Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | EGLN2 | Q96KS0 | 4/20 | 0.41 |
| ▸ | NSD2 | O96028 | 3/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 5/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17630050 | 0.81 | ALDH1A1 (0.41) | EGLN2NSD2CYP11B2KDM1AMAOB | |
| SCHEMBL17630030 | 0.81 | PLAU (0.43) | PTPN11EGLN2NSD2MAP4K4CYP11B2 | |
| SCHEMBL17629867 | 0.80 | PTPN11 (0.43) | PTPN11EGLN2NSD2MAP4K4CYP11B2 | |
| SCHEMBL9950905 | 0.78 | ADORA2A (0.43) | MAP4K4ALDH1A1KCNH2 | |
| SCHEMBL2406888 | 0.78 | PDK1 (0.46) | MAP4K4ALDH1A1 | |
| SCHEMBL16685761 | 0.76 | FYN (0.42) | ALDH1A1CYP2A6 | |
| SCHEMBL1773669 | 0.75 | DGAT1 (0.44) | ALDH1A1 | |
| SCHEMBL1765772 | 0.74 | KIF11 (0.47) | MAP4K4KDM1AMAOBALDH1A1 | |
| SCHEMBL3397294 | 0.74 | HRH3 (0.51) | PTPN11NSD2CYP11B2KDM1AHRH3 | |
| SCHEMBL17630103 | 0.73 | CYP11B1 (0.39) | PTPN11EGLN2NSD2MAP4K4CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040132720-A1 | Piperazine derivatives, their preparation and uses in therapy (5ht1b receptor activity) | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-07-08 | — | — | US | disclosed |
| EP-1368344-A1 | PIPERAZINE DERIVATIVES, THEIR PREPARATION AND USES IN THERAPY (5HT1B RECEPTOR ACTIVITY) | SMITHKLINE BEECHAM PLC (GB) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002074768-A1 | PIPERAZINE DERIVATIVES, THEIR PREPARATION AND USES IN THERAPY (5HT1B RECEPTOR ACTIVITY) | SMITHKLINE BEECHAM PLC (GB) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132720-A1 | Piperazine derivatives, their preparation and uses in therapy (5ht1b receptor activity) | SIGMAR1, HTR6, OPRL1 | PTPN11 1979/4885EGLN2 1873/4885NSD2 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.